Business Wire

Fintatech Announces Trading Chart Designer 2.0

Share

Fintatech, a custom trading software development company and provider of high-performance capital market solutions with a universal 'trading platform skeleton' in its core that is supplemented by interconnective module-based software components according to the client’s requirements, announces significant enhancements to their Trading Chart Designer software solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005640/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fintatech Trading Chart Designer 2.0 Release (Graphic: Business Wire)

Our current trading software solutions list is comprised of:

- Trading Chart Designer

- Trading Platform Designer

- Trading Data Server

Read on to learn more about our enhancements in Trading Chart Designer 2.0, including:

New indicators

Traders may use over 130 Technical Analysis Indicators on our platform to do the finest market analysis. We keep researching and adding new indicators, so that traders may make even more precise and better decisions. We introduced numerous new indicators to Trading Chart Designer version 2.0, including volume profile indicators: daily profiles, and visible range profile indicators.

Fintatech Scripting 2.0

Fintatech Scripting is a tool allowing customers to write their personal scripts; basically, bots that can trade independently. At first, traders establish the set of rules and strategies which will be executed by the program. In version 2.0, we:

  • Improved high-speed backtesting engine built on the latest .NET Core technology;
  • Added new indicators and corresponding strategy methods to make it easier to plot indicators in strategy code;
  • Added new performance metrics and optimization methods;
  • Several other minor fixes and enhancements.

Fintatech Paper Trading

Testing your approaches, learning to trade, practicing your abilities, and applying theoretical information have never been easier or less risky. All decisions and trading manipulations must satisfy the market's needs and actual trading goals in order for all of this to be as productive and lucrative as feasible for the trader. The same risk and return targets, investment limits, and trading horizon must be calculated for the paper investor as well as for the existing account. This is how you can learn and improve your results with Fintatech Paper Trading.

Fundamental Data View Widget

The efficiency and need for fundamental analysis are hotly debated. Basic information on the company and its present market position, on the other hand, is important for all sorts of analyses. It will undoubtedly be helpful while making critical decisions.

That's why we've incorporated a widget into our platform that displays fundamental data. From now on, you can get all the information you need, from a brief overview of the company's operations to its market capitalization in one place and with just one click.

Need a сustom trading software solution? Contact us to get free demo access.

Website: https://fintatech.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fintatech BV,
Fedir Nedashkovskyi
+3197010282855
sales@fintatech.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Enters into Antibody Agreement with ADC Therapeutics28.11.2022 15:47:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS

Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members28.11.2022 15:15:00 CET | Press release

Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand,an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/ Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire) Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website fo

Viz.ai Appoints Radiology Advisory Board to Advance Innovation28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology. “I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.” “I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board a

Viz.ai Launches AI-powered Viz™ Radiology Suite28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the introduction of an AI-powered radiology suite, specifically designed to alert the radiologist in their workflow of suspected diseases, prioritize worklists, and connect care teams in real-time. The Viz™ Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005172/en/ Screen shots of Viz Radiology Suite including worklist and PACS integration (Graphic: Business Wire) “With an increasing demand for imaging studies and a global shortage of radiologists, technologies that can be easily integrated into radiology workflows to enhance efficiency and streamline patient care are sorely needed,” said Allan Brook, M.D., FA

Wipro Launches AWS Skills Guild Program: Step Up28.11.2022 13:55:00 CET | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced the launch of its new Skills Guild with Amazon Web Services (AWS) at AWS re:Invent 2022. AWS Skills Guild is a comprehensive enablement program for large enterprises to build cloud skills through integrated delivery of AWS learning opportunities. Wipro Step Up will use the AWS Skills Guild framework to transform the way employees engage with clients on their AWS Cloud journeys. “As the world continues to evolve and cloud becomes the foundation for business success, we are doubling down on our strategic partnerships to advance our clients’ business goals and help them drive new competitive advantage in a rapidly changing world,” said Jason Eichenholz, Senior Vice President and Global Head of Ecosystems and Partnerships, Wipro Limited. “Our Skills Guild builds on our existing cloud capabilities and deepens our AWS competencies to help clients drive accelerated ROI from AWS

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom